NASDAQ: ABOSAcumen Pharmaceuticals Inc Stock
$4.95-0.22 (-4.26%)
Updated Jun 5, 2023
ABOS Price
$4.95
Fair Value Price
N/A
Market Cap
$203.07M
52 Week Low
$3.17
52 Week High
$10.97
P/E
-4.46x
P/B
1.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$45.03M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$37M
Beta
1.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ABOS Overview
Acumen Pharmaceuticals Inc. develops therapies for the treatment of Alzheimer's disease. Acumen's approach targets AbOs, a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques. The company's lead immunotherapy drug candidate ACU193, is a humanized monoclonal antibody that is in Phase I clinical-stage trials. Acumen Pharmaceuticals was incorporated in 1996 and is headquartered in Charlottesville, VA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABOS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ABOS is good value based on its book value relative to its share price (1.13x), compared to the US Biotechnology industry average (5.21x)
P/B vs Industry Valuation
ABOS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ABOS due diligence checks available for Premium users.
Be the first to know about important ABOS news, forecast changes, insider trades & much more!
ABOS News
Valuation
ABOS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.46x
Industry
11.59x
Market
53.21x
ABOS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.13x
Industry
5.21x
ABOS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABOS's financial health
Profit margin
Revenue
$0.0
Net Income
-$11.3M
Profit Margin
0%
ABOS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$187.9M
Liabilities
$8.8M
Debt to equity
0.05
ABOS's short-term assets ($144.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABOS's short-term assets ($144.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.2M
Investing
-$41.9M
Financing
$0.0
ABOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABOS vs Biotech Stocks
Acumen Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.